3-[1-(1,2,3,4-tetrahydro)quinolinyl]sulfonylaniline | 91619-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[1-(1,2,3,4-tetrahydro)quinolinyl]sulfonylaniline
• 英文别名: 3-(3,4-dihydro-1(2H)-quinolinylsulfonyl)aniline；3-(3,4-dihydro-2H-quinolin-1-ylsulfonyl)aniline
• CAS: 91619-41-9
• 化学式: C₁₅H₁₆N₂O₂S
• 分子量: 288.37
• InChiKey: QXQZYEACZOXSSN-UHFFFAOYSA-N

物化性质

• 熔点：
  99-101 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  502.6±60.0 °C(Predicted)
• 密度：
  1.329±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[1-(1,2,3,4-tetrahydro)quinolinyl]sulfonylaniline 在 三乙酰氧基硼氢化钠 作用下， 生成 3-{[[3-(3,4-dihydro-2H-quinoline-1-sulfonyl)-phenyl]-(3H-imidazol-4-ylmethyl)-amino]-methyl}-benzonitrile
  参考文献：
  名称：

  3-咪唑基甲基氨基苯基磺酰基四氢喹啉，一种新型的法呢基转移酶抑制剂。

  摘要：

  介绍了一系列的3-咪唑基甲基氨基苯基磺酰基四氢喹啉作为法呢基转移酶抑制剂的设计，合成及构效关系。提出了通过该系列抑制剂抑制法呢基转移酶的有效药效基团。

  DOI：

  10.1016/s0960-894x(99)00686-1
• 作为产物：
  描述：

  1-(3-硝基苯磺酰基)-1,2,3,4-四氢喹啉 在 tin(ll) chloride 作用下， 以 乙酸乙酯 为溶剂， 生成 3-[1-(1,2,3,4-tetrahydro)quinolinyl]sulfonylaniline
  参考文献：
  名称：

  3-咪唑基甲基氨基苯基磺酰基四氢喹啉，一种新型的法呢基转移酶抑制剂。

  摘要：

  介绍了一系列的3-咪唑基甲基氨基苯基磺酰基四氢喹啉作为法呢基转移酶抑制剂的设计，合成及构效关系。提出了通过该系列抑制剂抑制法呢基转移酶的有效药效基团。

  DOI：

  10.1016/s0960-894x(99)00686-1

文献信息

• FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
  申请人：Ohno Kohsuke

  公开号：US20090325900A1

  公开（公告）日：2009-12-31

  The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof and the like. In the formula (I), ring A represents 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; R A represents halogen, alkyl, alkenyl, alkynyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; ring B represents aryl or heteroaryl; R B represents halogen, alkyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; E 1 and E 2 represent an oxygen atom or the like; U represents a single bond or alkylene; X represents a group represented by Y, —SO 2 —Y, —O— (alkylene)-Y, —O-Z in which Y represents Z, amino or the like; Z represents cycloalkyl, heterocycloalkyl, aryl, heteroaryl or the like; or the like.

  本发明提供一种化合物，可用作预防或治疗与性激素依赖性疾病或类似疾病的药剂。即，本发明提供以下通式（I）所表示的融合杂环衍生物，包含其制药组合物、药用等。在式（I）中，环A表示5-成员环状不饱和碳氢化合物或5-成员杂芳基；RA表示卤素、烷基、烯基、炔基、羧基、烷氧基、氨基甲酰基、烷基甲酰基或类似物；环B表示芳基或杂芳基；RB表示卤素、烷基、羧基、烷氧基、氨基甲酰基、烷基甲酰基或类似物；E1和E2表示氧原子或类似物；U表示单键或烷基；X表示由Y表示的基团、—SO2—Y、—O—（烷基）-Y、—O-Z中的基团，其中Y表示氨基或类似物；Z表示环烷基、杂环烷基、芳基、杂芳基或类似物；或类似物。
• Fused pyramidine derivative and use thereof
  申请人：Hamamura Kazumasa

  公开号：US20070010537A1

  公开（公告）日：2007-01-11

  There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R 1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring A a is a 6-membered aromatic ring which may be further substituted, ring B a is a homocyclic or heterocyclic ring which may be further substituted, W a is an oxygen atom or a sulfur atom, X a1 and X a2 , which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or X a1 and X a2 together may form an oxygen atom, a sulfur atom or NR 3a (wherein R 3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Y a is C 1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

  提供了一种融合嘧啶化合物，具有抗促黄体激素释放激素的拮抗活性，以及含有该化合物的药物。一种促黄体激素释放激素拮抗剂，包含以下式子所代表的化合物：其中，R1a是一个可以被取代的碳氢基团或氢原子，环A是一个可以进一步取代的6元芳香环，环B是一个可以进一步取代的同环或异环，Wa是一个氧原子或硫原子，Xa1和Xa2，可能相同或不同，是每个可以被取代的碳氢基团或杂环基团，或Xa1和Xa2在一起可以形成氧原子、硫原子或NR3a（其中R3a是一个可以被取代的碳氢基团或氢原子），而Y是C1-6烷基，可以被取代或成为键，或其盐或前药。
• FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF
  申请人：Hamamura Kazumasa

  公开号：US20090062258A1

  公开（公告）日：2009-03-05

  The present invention provides a compound represented by the formula (I) and a salt thereof wherein: ring A is a 5-membered aromatic heterocycle optionally having substituent(s); R 1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); W is an oxygen atom or a sulfur atom; X 1 and X 2 may be the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group, or, X 1 and X 2 in combination, optionally, form an oxygen atom, a sulfur atom or ═NR 2 ; ring B is an aromatic ring optionally further having substituent(s); Y is a bond, C 1-6 alkylene C 2-6 alkenylene or C 2-6 alkynylene, optionally having substituent(s); and Z is —SO n R 3 or —COR 4 , which are useful as a pharmaceutical agent having GnRH antagonistic action.

  本发明提供了一种由式(I)表示的化合物及其盐，其中：环A是一个可选具有取代基的5元芳香杂环；R1是氢原子或一个可选具有取代基的碳氢基；W是氧原子或硫原子；X1和X2可以相同或不同，每个都是氢原子、可选具有取代基的碳氢基或杂环基，或者X1和X2组合，可选地形成氧原子、硫原子或═NR2；环B是一个可选进一步具有取代基的芳香环；Y是键，C1-6烷基C2-6烯基或C2-6炔基，可选具有取代基；Z是—SOnR3或—COR4，其作为具有GnRH拮抗作用的药物剂使用。
• NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES
  申请人：Yonekubo Shigeru

  公开号：US20100112090A1

  公开（公告）日：2010-05-06

  [Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; R A and R B are independently halogen, cyano, alkyl, alkylsulfonyl, —OW 1 , —SW 1 , —COW 2 , —NW 3 W 4 , —SO 2 NW 3 W 4 , aryl, etc.; R C is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, —CO—Y, —SO 2 —Y, —S-(alkylene)-Y, —O-(alkylene)-Y, —SO 2 -(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

  [目的]本发明提供一种化合物，可用作预防或治疗性激素依赖性疾病等药物。 [解决方案]本发明提供一种氮杂环融合衍生物，其具有GnRH拮抗活性，包括前药、盐、含有该化合物的药物组成物、药物用途等。该化合物的通式(I)如下：在式(I)中，环A和环B独立地是芳基或杂芳基；RA和RB独立地是卤素、氰基、烷基、烷基磺酰、—OW1、—SW1、—COW2、—NW3W4、—SO2NW3W4、芳基等；RC是氢或烷基；E是氧原子等；U是单键或烷基；X是Y、—CO—Y、—SO2—Y、—S-(烷基)-Y、—O-(烷基)-Y、—SO2-(烷基)-Y等；Y是Z或氨基等；Z是环烷基、杂环烷基、芳基、杂芳基等。
• FUSED PYRIMIDINE DERIVATIVE AND USES THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1847541A1

  公开（公告）日：2007-10-24

  A compound represented by the formula (I) wherein ring A is a 5-membered aromatic heterocycle optionally having substituent(s), R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), W is an oxygen atom or a sulfur atom, X1 and X2 may be the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group, or, X1 and X2 in combination optionally form an oxygen atom, a sulfur atom or =NR2, ring B is an aromatic ring optionally further having substituent(s), Y is a bond, C1-6 alkylene C2-6 alkenylene or C2-6 alkynylene, optionally having substituent(s), and Z is a group represented by formula: -SOnR3, or a group represented by formula: -COR4, or a salt thereof, is useful as a pharmaceutical agent having GnRH antagonistic action.

  由式 (I) 代表的化合物 其中环 A 是可选具有取代基的 5 元芳香杂环、 R1 是氢原子或可选具有取代基的烃基、 W 是氧原子或硫原子、 X1 和 X2 可以相同或不同，各自为氢原子、可选具有取代基的烃基或杂环基，或者，X1 和 X2 组合可选形成氧原子、硫原子或 =NR2、 环 B 是芳香环，可选择进一步具有取代基、 Y 是键、C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，可选择具有取代基，以及 Z 是由式-SOnR3，或由式表示的基团：-COR4，或其盐，可用作具有 GnRH 拮抗作用的药剂。